BioLineRx Ltd.
BLRX
$2.94
-$0.16-5.16%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.13% | 78.52% | 126.73% | 173.94% | 232.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.08% | 51.44% | 58.49% | 63.91% | 44.48% |
| Operating Income | 29.55% | -1.66% | -21.99% | -47.45% | -44.48% |
| Income Before Tax | 62.03% | 30.42% | -52.71% | -142.93% | -123.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 62.03% | 30.42% | -52.71% | -142.93% | -123.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.03% | 30.42% | -52.71% | -142.93% | -123.01% |
| EBIT | 29.55% | -1.66% | -21.99% | -47.45% | -44.48% |
| EBITDA | 34.07% | 1.11% | -20.22% | -47.96% | -44.71% |
| EPS Basic | 68.25% | 37.78% | -30.26% | -93.88% | -74.46% |
| Normalized Basic EPS | 79.44% | 50.49% | -14.75% | -74.63% | -74.02% |
| EPS Diluted | 68.25% | 37.78% | -30.26% | -93.88% | -74.46% |
| Normalized Diluted EPS | 79.44% | 50.49% | -14.75% | -74.63% | -74.02% |
| Average Basic Shares Outstanding | 23.32% | 22.23% | 21.60% | 24.48% | 28.28% |
| Average Diluted Shares Outstanding | 23.32% | 22.23% | 21.60% | 24.48% | 28.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
